Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

(2011) J. B. Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

A clinical perspective of IL-1β as the gatekeeper of inflammation

(2011) Charles A. Dinarello   EUROPEAN JOURNAL OF IMMUNOLOGY

NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment

(2011) Jasmin B Kuemmerle-Deschner et al.   ARTHRITIS RESEARCH & THERAPY

Risk factors for severe Muckle-Wells syndrome

(2010) Jasmin B. Kümmerle-Deschner et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome

(2010) Jasmin B. Kuemmerle-Deschner et al.   ARTHRITIS AND RHEUMATISM

Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever

(2009) T. Kallinich et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin

(2008) Helmut Wittkowski et al.   ARTHRITIS AND RHEUMATISM

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome

(2008) Raphaela Goldbach-Mansky et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM